A Clinical Study in Cancer Patients to Investigate the Potential Impact of Custirsen, on the Blood Levels of the Chemotherapeutic Drug, Paclitaxel, When Given Together as Part of a Treatment Regimen
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Achieve Life Sciences
With
Teva Branded Pharmaceutical Products R&D, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Confirmed diagnosis of a solid tumor that is refractory to standard therapies and is not amenable to treatment with established curative or palliative therapies and for whom paclitaxel and carboplatin is deemed an acceptable treatment by the investigator
Males or females ≥18 years of age
Life expectancy of ≥12 weeks
Minimum of 1 lesion
ECOG performance status of 0, 1 or 2
Adequate bone marrow reserve
Adequate renal and liver function
You may not be if
Brain metastases that are symptomatic or require ongoing treatment
Major trauma or surgery within last 2 months, acute infection within 2 weeks (14 days), or radiotherapy, chemotherapy, immunotherapy or hormonal therapy within past 4 weeks
Persistent grade 2 or greater toxicity related to prior therapy
Grade 2 or greater peripheral neuropathy
Recent or current use of Cyp3A4, Cyp2C8 or P-gp inhibitors
Recent or current use of CYP enzyme inducers
Clareo Health | A Clinical Study in Cancer Patients to Investigate the Potential Impact of Custirsen, on the Blood Levels of the Chemotherapeutic Drug, Paclitaxel, When Given Together as Part of a Treatment Regimen
